NASDAQ losers: Chelsea Therapeutics International (NASDAQ:CHTP), Pharmacyclics (NASDAQ:PCYC), ZIOPHARM Oncology (NASDAQ:ZIOP), Array Biopharma (NASDAQ:ARRY)

Some drugs that have gained approval this year so far include AstraZeneca’s Myalept (complications of leptin deficiency) and Farxiga (type II diabetes), Chelsea Therapeutics International Ltd. (NASDAQ:CHTP) (to treat neurogenic orthostatic hypotension), BioMarin’s Vimizim (Morquio A syndrome) and Vanda Pharma’s Hetlioz. Chelsea Therapeutics International Ltd. (NASDAQ:CHTP) stock performance was -5.75% in last session and finished the day at $4.92. Traded volume was 3.02million shares in … Continue reading NASDAQ losers: Chelsea Therapeutics International (NASDAQ:CHTP), Pharmacyclics (NASDAQ:PCYC), ZIOPHARM Oncology (NASDAQ:ZIOP), Array Biopharma (NASDAQ:ARRY)

Biotech Losers: MannKind Corporation (NASDAQ:MNKD), Rexahn Pharmaceuticals (NYSEMKT:RNN), ZIOPHARM Oncology (NASDAQ:ZIOP), Seattle Genetics (NASDAQ:SGEN)

MannKind Corporation (NASDAQ:MNKD) announced that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) date for AFREZZA(R) by three months to July 15, 2014 in order to provide time for a full review of information submitted by MannKind in response to the FDA’s requests.MannKind Corporation (NASDAQ:MNKD) stock performance was -6.42% in last session and finished the day at … Continue reading Biotech Losers: MannKind Corporation (NASDAQ:MNKD), Rexahn Pharmaceuticals (NYSEMKT:RNN), ZIOPHARM Oncology (NASDAQ:ZIOP), Seattle Genetics (NASDAQ:SGEN)

On Apr 3, Zacks Investment Research upgraded ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) to Zacks Rank #1 (Strong Buy). ZIOPHARM Oncology Inc. (NASDAQ:ZIOP)’s loss estimates have declining on the back of better-than-expected fourth quarter 2013 results. ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) stock performance was -6.06% in last session and finished the day at $4.34. Traded volume was 1.86million shares in the last session and the average volume of … Continue reading Biotech losers: ZIOPHARM Oncology (NASDAQ:ZIOP), Sangamo Biosciences (NASDAQ:SGMO), Lexicon Pharmaceuticals (NASDAQ:LXRX), XOMA Corp (NASDAQ:XOMA)

Looking back to 160 days ago, ZIOPHARM Oncology Inc (NASDAQ:ZIOP) priced a 14,300,000 share secondary stock offering at $3.50 per share. Buyers in that offering made a considerable investment into the company, expecting that their investment would go up over the course of time and based on early trading on Wednesday. ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) stock performance was -3.75% in last session and finished the … Continue reading Volatile Stocks at Biotech: ZIOPHARM Oncology (NASDAQ:ZIOP), Idenix Pharmaceuticals (NASDAQ:IDIX), Synthetic Biologics (NYSEMKT:SYN), Ariad Pharmaceuticals (NASDAQ:ARIA)

Fate Therapeutics Inc (NASDAQ:FATE) recently issued a statement that it has enrolled it first patient for the second phase of this study. The primary aim of the PUMA study is to assess the efficacy and safety of PROHEMA in a randomized, controlled environment for patients that are under treatment for hematopoietic stem cell or HSC transplantation for hematologic malignancies. Fate Therapeutics Inc (NASDAQ:FATE) stock performance … Continue reading Biotech Gainers: Fate Therapeutics Inc (NASDAQ:FATE), ZIOPHARM Oncology (NASDAQ:ZIOP), Uniqure NV (NASDAQ:QURE), Sorrento Therapeutics (NASDAQ:SRNE)

Shares of ZIOPHARM Oncology (NASDAQ:ZIOP) saw a significant decrease in short interest in December. As of December 15th, there was short interest totalling 17,601,779 shares, a decrease of 5.8% from the November 28th total of 18,695,183 shares, AnalystRatingsNetwork.com reports. ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) belongs to Healthcare sector. Its weekly performance is 8.10%. On last trading day company shares ended up $5.07. ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) … Continue reading Top Morning News: ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP), Barrick Gold Corporation (NYSE:ABX), FireEye, Inc. (NASDAQ:FEYE), Cass Information Systems (NASDAQ:CASS), Power Solutions International (NASDAQ:PSIX)